• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Romania Pharmaceuticals and Healthcare Report Q1 2013 - Product Image

Romania Pharmaceuticals and Healthcare Report Q1 2013

  • ID: 2373654
  • January 2013
  • Region: Romania
  • 93 pages
  • Business Monitor International

FEATURED COMPANIES

  • Actavis Romania (Sindan)
  • Company Profiles
  • LaborMed Pharma
  • Merck & Co
  • Novartis
  • Roche
  • MORE

BMI View:

While it is clear that drugmakers operating in Romania are far from happy with the latest revisions to the pharmaceutical claw-back tax, and the tax remains unfairly punitive, all things considered, the August 2012 amendments are a small improvement, though definitely not what producers would have wanted ideally. With part of the objective of the claw-back tax to improve the timeliness of payments for reimbursed medicines, which has been a major difficulty for drug producers and distributors over the last four years, there are some upsides to this mechanism working effectively. The tax remains most punitive for generic drugmakers with lower-value medicines and could lead to these cheaper medicines exiting the market. The tax continues to weigh on BMI's assessment of Romania's Pharmaceutical and Healthcare Risk/Reward ratings.

Headline Expenditure Projections:

- Pharmaceuticals: RON12.76bn (US$4.18bn) in 2011 to RON13.52bn (US$3.78bn) in 2012;
+6.0% in local currency terms and -9.7% in US dollar terms. Local currency forecast slightly down from Q412 on account of macroeconomic factors; US dollar forecast further impacted by exchange rate factors.

- READ MORE >

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Actavis Romania (Sindan)
  • Company Profiles
  • LaborMed Pharma
  • Merck & Co
  • Novartis
  • Roche
  • MORE

Executive Summary 5

SWOT Analysis 7

Romania Pharmaceuticals And Healthcare Industry SWOT 7

Romania Political SWOT 8

Romania Economic SWOT 8

Romania Business Environment SWOT 8

Pharmaceutical Risk/Reward Ratings 9
Table: Emerging Europe Pharmaceutical Risk/Reward Ratings, Q113 9

Rewards 10

Risks 10

Romania - Market Summary 12

Regulatory Regime 13
Table: NMA Authorisation Activity, 2007-2008 13

Pharmaceutical Advertising 14

Intellectual Property Regime 14

Corruption 17

Pricing Regime 17

Reimbursement Regime 18

Co-Payments for Medical Services 19

Public Sector Procurement 20

Claw-Back Tax 21

Latest Claw-Back Tax Developments 22

Industry Developments 24

Epidemiology 24

Communicable Diseases 25

Healthcare System 25

Private Healthcare Provision 26

Private Healthcare Provision Developments 27

Healthcare Reform 28

Pharmaceutical Payment Delays 31

Research and Development (R&D) 31

Clinical Trials 32

Medical Devices 32

Industry Forecast Scenario 34

Pharmaceutical Market Forecast 34
Table: Romania Pharmaceutical Sales, Historical Data and Forecasts 35

Healthcare Market Forecast 37
Table: Romania Healthcare Expenditure Trends, Historical Data and Forecasts 38
Table: Romania Government Healthcare Expenditure Trends, Historical Data and Forecasts 39
Table: Romania Private Healthcare Expenditure Trends, Historical Data and Forecasts 39

Key Growth Factors - Macroeconomic 40

Prescription Drug Market Forecast 41
Table: Romania Prescription Drug Market Indicators, Historical Data and Forecasts 42

Patented Drug Market Forecast 43
Table: Romania Patented Drug Market Indicators, Historical Data and Forecasts 44

Generic Drug Market Forecast 45
Table: Romania Generics Drug Market Indicators, Historical Data and Forecasts 46

OTC Medicine Market Forecast 47
Table: OTC Medicine Sales By Subsector, 2007-2010 48
Table: Romania Over-The-Counter (OTC) Medicine Market Indicators, Historical Data and Forecasts 49

Pharmaceutical Trade Forecast 50
Table: Romania Pharmaceutical Trade Data And Forecasts (US$mn) 52
Table: Romania Pharmaceutical Trade Data And Forecasts (RONmn) 52

Medical Device Market Forecast 53
Table: Romania Medical Device Market Indicators, Historical Data and Forecasts 54

Other Healthcare Data 55

Key Risks To BMI's Forecast Scenario 56

Competitive Landscape 57

Pharmaceutical Industry 57

Domestic Pharmaceutical Sector 57

Foreign Pharmaceutical Sector 58
Table: Members of ARPIM, 2011 58

Pharmaceutical Company Developments 59

Pharmaceutical Wholesaling 60

Pharmaceutical Retail 62
Table: Pharmacies & Pharmaceutical Storehouses, 2000-2006 (000s) 62

Company Profiles 63

Local Companies 63

Zentiva Romania 63

Actavis Romania (Sindan) 65

Terapia Ranbaxy 67

Antibiotice Ia?i 69

LaborMed Pharma 73

Multinational Companies 75

GlaxoSmithKline (Europharm) 75

Roche 77

Sanofi 78

Novartis 79

Pfizer 80

Krka 81

Merck & Co 82

Demographic Outlook 83
Table: Romania's Population By Age Group, 1990-2020 ('000) 84
Table: Romania's Population By Age Group, 1990-2020 (% of total) 85
Table: Romania's Key Population Ratios, 1990-2020 86

Glossary 87

BMI Methodology 89

How We Generate Our Pharmaceutical Industry Forecasts 89

Pharmaceutical Risk/Reward Ratings Methodology 90

Ratings Overview 90
Table: Pharmaceutical Business Environment Indicators 91

Weighting 92
Table: Weighting Of Components 92

Sources 92

Note: Product cover images may vary from those shown

Company Profiles
Local Companies
Zentiva Romania
Actavis Romania (Sindan)
Terapia Ranbaxy
Antibiotice Ia?i
LaborMed Pharma
Multinational Companies
GlaxoSmithKline (Europharm)
Roche
Sanofi
Novartis
Pfizer
Krka
Merck & Co

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos